Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoven versus Vaminolact in premature ELBW infants
2009-012603-26Phase 3Completed
- Sponsor
- Fresenius Kabi
- Start
- Feb 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in extremely low birth weight (ELBW) comparing Neoven with Vaminolact (2 arms). Primary endpoints: Hyperammonemia, Azotemia and 3 more. Started Feb 2010; status: completed.
02
Drugs
NeovenVaminolact
03
Conditions
extremely low birth weight (ELBW)
Beyond the preview
Go deeper on 2009-012603-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012603-26.